---
title: "Competing Risks of Loss to Follow-up and Mortality on ART in Northern Ghana: Fine‑Gray Analysis"
id: "medrxiv-23-assessing-the-competing-risks-of-loss-to-follow-up-and-mortality-among-adults"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-23-assessing-the-competing-risks-of-loss-to-follow-up-and-mortality-among-adults"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.15.26365612v1?rss=1"
published_at: "2026-10-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Competing Risks of Loss to Follow-up and Mortality on ART in Northern Ghana: Fine‑Gray Analysis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-23-assessing-the-competing-risks-of-loss-to-follow-up-and-mortality-among-adults
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.15.26365612v1?rss=1)
- **Published At:** 2026-10-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Retrospective cohort of 329 adults living with HIV who initiated **antiretroviral therapy** at Nalerigu Baptist Medical Centre between January 2013 and December 2019; investigators used a competing‑risks framework to avoid bias from mutually exclusive outcomes. - The study team applied the **Fine-Gray** subdistribution hazard model to estimate predictors of **loss to follow-up** (LTFU) and death while accounting for the competing event; cause‑specific Cox models were fitted for sensitivity analysis. - Incidence rates reported: 2.2 per 100 person‑months for LTFU (95% CI: 1.9–2.6) and 0.74 per 100 person‑months for death (95% CI: 0.57–0.98); at 36 months cumulative incidence was 50.2% for LTFU and 16.0% for death. - Predictors from subdistribution hazard models: residing closer to clinic associated with lower LTFU (SHR = 0.68, 95% CI: 0.49–0.93); higher baseline weight increased LTFU risk (SHR = 1.02 per kg, 95% CI: 1.00–1.04). - Mortality associations in subdistribution models: efavirenz‑based regimens linked with lower mortality (SHR = 0.27, 95% CI: 0.15–0.50); female sex associated with lower mortality (SHR = 0.39, 95% CI: 0.18–0.85); higher baseline weight associated with reduced mortality (SHR = 0.93 per kg, 95% CI: 0.90–0.96). - Findings in cause‑specific Cox proportional hazards models were reported as broadly consistent with Fine‑Gray results, according to the authors. - Data access is controlled under institutional ethics approval; a de‑identified minimal dataset and analysis code are deposited in Zenodo and GitHub under controlled access. The investigators reported institutional ethics approval from CHRPE, Kwame Nkrumah University of Science and Technology (Approval No. CHRPE/AP/1181/26). - The article is a medRxiv preprint and has not been peer‑reviewed; the authors declared no competing interests and confirmed participant consent and IRB/oversight compliance.
## Clinical Analysis & Structured Key Points
Retention in antiretroviral therapy (ART) programmes remains a major public health challenge in HIV care, with loss to follow-up (LTFU) and death threatening treatment success. Because these outcomes are competing events, conventional survival methods may yield biased estimates of their incidence and associated risk factors. To estimate the cumulative incidence of LTFU and mortality and identify factors associated with these outcomes among adults receiving ART in Northern Ghana using a competing-risks framework. We conducted a retrospective cohort study of 329 adults living with HIV who initiated ART at Nalerigu Baptist Medical Centre, Ghana, between January 2013 and December 2019. Fine--Gray subdistribution hazard models were used to evaluate predictors of LTFU and death while accounting for competing risks. Cause-specific Cox proportional hazards models were fitted as a sensitivity analysis. The incidence rates were 2.2 per 100 person-months (95% CI: 1.9--2.6) for LTFU and 0.74 per 100 person-months (95% CI: 0.57--0.98) for death. At 36 months, the cumulative incidence was 50.2% for LTFU and 16.0% for death. Patients residing closer to the clinic had a lower cumulative incidence of LTFU than those living farther away (SHR = 0.68, 95% CI: 0.49--0.93), whereas higher baseline weight was associated with increased LTFU (SHR = 1.02 per kg, 95% CI: 1.00--1.04). Mortality was lower among patients receiving efavirenz-based regimens (SHR = 0.27, 95% CI: 0.15--0.50), females (SHR = 0.39, 95% CI: 0.18--0.85), and those with higher baseline weight (SHR = 0.93 per kg, 95% CI: 0.90--0.96). Findings were broadly consistent in cause-specific Cox models. LTFU was substantially more frequent than mortality among adults receiving ART in Northern Ghana. Travel distance to the treatment facility was an important barrier to retention, while ART regimen, sex, and baseline weight were associated with mortality. Expanding access to ART services through decentralized and community-based models may improve retention and support efforts to achieve HIV control targets.
## Related Clinical Research

- [Global stakeholder priorities for point-of-care HIV NAATs: sensitivity, speed, and fingerstick sam](https://medichelpline.com/clinical-feed/plos-one-11-global-stakeholder-preferences-for-point-of-care-hiv-nucleic-acid-amplification.md)
- [Monitoring doxy-PEP impact: when to reassess guidance on STI prophylaxis](https://medichelpline.com/clinical-feed/plos-medicine-0-how-do-we-monitor-doxy-pep-impact-and-when-should-we-consider-revisiting.md)
- [Violence and HIV outcomes in female sex workers: global systematic review and meta-analysis](https://medichelpline.com/clinical-feed/plos-medicine-3-impact-of-violence-on-hiv-outcomes-among-female-sex-workers-a-global-systematic.md)
- [Diimide and Hydrazone Scaffolds as Novel LRAs for HIV-1 Shock-and-Kill Strategies](https://medichelpline.com/clinical-feed/pubmed-42735590.md) (DOI: 10.1016/j.bbrc.2026.154580)
- [National development predicts government responses to the 2025 **PEPFAR** funding freeze](https://medichelpline.com/clinical-feed/medrxiv-13-cross-national-factors-associated-with-governmental-responses-to-the-2025.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.